Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma

Oncogenesis

Volumn 1, Issue 7, 2012, Pages

  Fernandez Alvarez A ^a   Llorente Izquierdo, C ^b   Mayoral, R ^b,c   Agra, N ^b   Bosca L ^b,c   Casado, M ^a,c   Martin Sanz P ^b,c  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

COX 2; HCC; histone acetylation; promoter methylation; survival

Indexed keywords

CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR;

5' UNTRANSLATED REGION; ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; DEACETYLATION; DNA METHYLATION; EPIGENETICS; HEPATOMA CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84868291951     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.23     Document Type: Article

References (45)

1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437. (Pubitemid 39096597)
2. Ledwith BJ, Pauley CJ, Wagner LK, Rokos CL, Alberts DW, Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 1997; 272: 3707-3714. (Pubitemid 27067016)
3. Martin-Sanz P, Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L. Expression of cyclooxygenase-2 in foetal rat hepatocytes stimulated with lipopolysaccharide and pro-inflammatory cytokines. Br J Pharmacol 1998; 125: 1313-1319. (Pubitemid 28542542)
4. Casado M, Callejas NA, Rodrigo J, Zhao X, Dey SK, Bosca L et al. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J 2001; 15: 2016-2018.
5. Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA 2001; 98: 8885-8890. (Pubitemid 32678122)
6. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology 2003; 125: 556-571. (Pubitemid 36929437)
7. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006; 66: 7059-7066. (Pubitemid 44197682)
8. Mayoral R, Fernandez-Martinez A, Bosca L, Martin-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005; 26: 753-761. (Pubitemid 41214337)
9. Cusimano A, Fodera D, Lampiasi N, Azzolina A, Notarbartolo M, Giannitrapani L et al. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann NY Acad Sci 2009; 1155: 300-308.
10. Cheng AS, Yu J, Lai PB, Chan HL, Sung JJ. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun 2008; 374: 175-180.
11. Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53: 1665-1672. (Pubitemid 39434113)
12. Cervello M, Foderaa D, Florena AM, Soresi M, Tripodo C, D'Alessandro N et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 2005; 11: 4638-4643. (Pubitemid 41179515)
13. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29: 688-696. (Pubitemid 29109581)
14. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007; 46: 108-125. (Pubitemid 46661865)
15. Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem Soc Trans 2008; 36(Pt 3): 543-545. (Pubitemid 351839376)
16. de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 2007; 25: 4887-4894. (Pubitemid 350220418)
17. Murata H, Tsuji S, Tsujii M, Sakaguchi Y, Fu HY, Kawano S et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab Invest 2004; 84: 1050-1059. (Pubitemid 39025039)
18. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004; 103: 2135-2142. (Pubitemid 38326230)
19. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009; 29: 4325-4339.
20. Yue X, Yang F, Yang Y, Mu Y, Sun W, Li W et al. Induction of cyclooxygenase-2 expression by hepatitis B virus depends on demethylation- associated recruitment of transcription factors to the promoter. Virol J 2011; 8: 118.
21. Hur K, Song SH, Lee HS, Ho Kim W, Bang YJ, Yang HK. Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. Biochem Biophys Res Commun 2003; 310: 844-851. (Pubitemid 37188699)
22. Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK et al. Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 50 CpG island in human gastric carcinoma cells. Cancer Res 2001; 61: 4628-4635. (Pubitemid 32685799)
23. Callejas NA, Bosca L, Williams CS, Du BR, Martin-Sanz P. Regulation of cyclooxygenase expression in hepatocytes by CCAAT/enhancer-binding proteins. Gastroenterology 2000; 119: 493-501. (Pubitemid 30621999)
24. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932. (Pubitemid 41830186)
25. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196. (Pubitemid 27435555)
26. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168. (Pubitemid 39140958)
27. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann NY Acad Sci 2009; 1155: 293-299.
28. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298. (Pubitemid 46439286)
29. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-1378. (Pubitemid 37175085)
30. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-1128.
31. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-2722. (Pubitemid 47494371)
32. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793. (Pubitemid 43980599)
33. Yang JD, Seol SY, Leem SH, Kim YH, Sun Z, Lee JS et al. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci 2011; 26: 1428-1438.
34. Mossman D, Kim KT, Scott RJ. Demethylation by 5-aza-20-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 2010; 10: 366.
35. Xia D, Wang D, Kim SH, Katoh H, Dubois RN. Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat Med 2012; 18: 224-226.
36. Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M et al. Cyclooxygenase-mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol 2002; 17: 1110-1116.
37. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011; 54: 939-947.
38. Vidali G, Boffa LC, Bradbury EM, Allfrey VG. Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 1978; 75: 2239-2243. (Pubitemid 8350742)
39. Tong X, Yin L, Joshi S, Rosenberg DW, Giardina C. Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem 2005; 280: 15503-15509. (Pubitemid 40616665)
40. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 2005; 280: 32569-32577. (Pubitemid 41368298)
41. Choi YH. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 2005; 27: 473-479.
42. Liu YW, Wang SA, Hsu TY, Chen TA, Chang WC, Hung JJ. Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase expression in RAW264.7 cells. J Cell Biochem 2010; 110: 1430-1438.
43. Park GY, Joo M, Pedchenko T, Blackwell TS, Christman JW. Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 2004; 286: L956-L962. (Pubitemid 38508805)
44. Casado M, Molla B, Roy R, Fernandez-Martinez A, Cucarella C, Mayoral R et al. Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes. Hepatology 2007; 45: 631-638. (Pubitemid 46450614)
45. Fernandez-Alvarez A, Soledad Alvarez M, Cucarella C, Casado M. Characterization of the human insulin-induced gene 2 (INSIG2) promoter: the role of Ets-binding motifs. J Biol Chem 2010; 285: 11765-11774.